Thrivent Financial for Lutherans Has $5.14 Million Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

Thrivent Financial for Lutherans raised its stake in United Therapeutics Co. (NASDAQ:UTHR) by 33.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 14,332 shares of the biotechnology company’s stock after buying an additional 3,615 shares during the quarter. Thrivent Financial for Lutherans’ holdings in United Therapeutics were worth $5,136,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in UTHR. ClariVest Asset Management LLC lifted its position in United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 42 shares in the last quarter. V Square Quantitative Management LLC acquired a new stake in shares of United Therapeutics in the 2nd quarter valued at about $30,000. Innealta Capital LLC bought a new stake in shares of United Therapeutics in the second quarter valued at about $33,000. USA Financial Formulas acquired a new position in shares of United Therapeutics during the third quarter worth about $33,000. Finally, Capital Performance Advisors LLP bought a new position in shares of United Therapeutics during the third quarter worth about $82,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Buying and Selling

In other United Therapeutics news, CFO James Edgemond sold 7,785 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the transaction, the chief financial officer now owns 2,615 shares in the company, valued at $947,597.55. This trade represents a 74.86 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 269 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $348.41, for a total transaction of $93,722.29. Following the completion of the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $45,293.30. The trade was a 67.42 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 117,496 shares of company stock valued at $43,765,042. Company insiders own 11.90% of the company’s stock.

United Therapeutics Stock Up 1.5 %

NASDAQ:UTHR opened at $372.89 on Friday. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $417.82. The stock’s 50 day moving average price is $365.06 and its two-hundred day moving average price is $331.82. The firm has a market capitalization of $16.65 billion, a price-to-earnings ratio of 16.38, a P/E/G ratio of 1.07 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $748.90 million for the quarter, compared to analysts’ expectations of $722.62 million. During the same quarter in the prior year, the business earned $5.38 EPS. The firm’s revenue for the quarter was up 22.9% on a year-over-year basis. Equities research analysts expect that United Therapeutics Co. will post 25.22 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on UTHR shares. The Goldman Sachs Group boosted their target price on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research note on Friday, November 1st. Jefferies Financial Group increased their target price on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a report on Monday, September 23rd. TD Cowen lifted their price target on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, October 21st. HC Wainwright increased their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Finally, Oppenheimer lifted their target price on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $370.86.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.